Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report

Read full text Summarise with VIRAT
Authors: Vassiliki T. Labropoulou, Evgenia Verigou, Eleni P. Kourea, Maria Liga, Dimitrios Tsokanas, Krisela‐Christina Valera, Alexandros Spyridonidis
Cited by: 0
References: 42

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies. The optimal therapeutic approach for relapsed/refractory (R/R) AITL remains therefore uncertain and challenging, with an unmet need for effective treatment options. Given the role of epigenetic alterations in AITL lymphomagenesis, the development of drugs targeting epigenetics may present a promising therapeutic approach. Belinostat, a histone deacetylase (HDAC) inhibitor, induced durable partial remission in heavily pretreated relapsed/refractory angioimmunoblastic T‐cell lymphoma, highlighting its potential as an effective therapeutic option when standard treatments and stem cell transplantation are unsuitable.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Histone Deacetylase Inhibitors Research Viral-associated cancers and disorders

Publication details

Journal / source
Clinical Case Reports
Volume
14
Issue
4
Publication date
25 March 2026
Language
EN